Clearmind Medicine Inc. (CMND)
| Market Cap | 3.40M -31.4% |
| Revenue (ttm) | n/a |
| Net Income | -6.64M |
| EPS | -170.45 |
| Shares Out | 1.02M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 164,246 |
| Open | 3.280 |
| Previous Close | 3.340 |
| Day's Range | 3.260 - 3.550 |
| 52-Week Range | 2.100 - 524.000 |
| Beta | -1.24 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jun 26, 2026 |
About CMND
Clearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. The company develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression. It develops MEAI compound for the treatment of alcohol use disorder, obesity, and metabolic disorders, as well as an alcohol substitute consumer product; a... [Read more]
Financial Performance
Financial StatementsNews
Clearmind Medicine to Feature New Insights from CMND-100 Psychedelic Clinical Trial on “Inside MEAI” Webinar
Yale and Johns Hopkins Researchers to Present Early Findings on MEAI Next Week in Live Webinar Yale and Johns Hopkins Researchers to Present Early Findings on MEAI Next Week in Live Webinar
Clearmind Medicine files Japanese patent application for 5-Methoxy-2-aminoindan
Clearmind Medicine (CMND) announced the publication of a Japanese patent application for its proprietary compositions comprising 5-Methoxy-2-aminoindan for the treatment of depression.
Clearmind Medicine Advances Global Intellectual Property Portfolio with Japanese Patent Filing for Innovative Psychedelic- Based Depression Treatment
Vancouver, Canada, May 29, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of ...
Clearmind Medicine announces JHM-IRB approval to advance CMND-100 trial
Clearmind Medicine (CMND) announced that the Johns Hopkins Medicine Institutional Review Board, JHM-IRB, has granted approval for its ongoing Phase I/II clinical trial of CMND-100. Dr. Adi Zuloff-Shan...
Clearmind Medicine Announces Johns Hopkins IRB Approval to Advance CMND-100 Phase I/II Clinical Trial to the Next Parts
Vancouver, Canada, May 26, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of ...
Clearmind Medicine Inc trading halted, news pending
19:50 EDT Clearmind Medicine (CMND) Inc trading halted, news pending
Clearmind Medicine announces 1-for-10 reverse share split
Clearmind Medicine (CMND) announced that it will conduct a reverse share split of its issued and outstanding common shares, no par value, at a ratio of 1-for-10. The reverse split…
Clearmind Medicine Announces 1-for-10 Reverse Share Split
Vancouver, Canada, May 19, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of ...
Clearmind Medicine signs new research agreement with Yissum Research Development
Clearmind Medicine (CMND) announced the signing of a new research agreement with Yissum Research Development Company of the Hebrew University of Jerusalem. The agreement will fund a preclinical study ...
Clearmind Medicine Signs Agreement to Examine MEAI in Combination and Sequencing with Tirzepatide Against Blockbuster GLP-1 Medications
Vancouver, Canada, May 18, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of ...
Clearmind Medicine CEO Dr. Adi Zuloff-Shani named Delegate to Federal Policy Summit on Psychedelic Medicine in Washington, D.C.
Federal Officials, Researchers, Clinicians and Biopharma Leadership Convene d by Psychedelic Medicine Coalition at the National Press Club
Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants Now Treated in Ongoing Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder
Vancouver, Canada, May 12, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of ...
Clearmind Medicine Announces “Inside MEAI” Webinar Featuring New Insights from CMND-100 Psychedelic Clinical Trial
Registration Now Open - Join the Live Webinar on June 10, 2026 Vancouver, Canada, May 11, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“ Clearmind ” or the “ Company ”), a clinica...
Clearmind Medicine files European patent application for psychedelic compounds
Clearmind Medicine (CMND) announced the filing of a European patent application for innovative psychedelic compounds targeting the treatment of Post-Traumatic Stress Disorder and other mental health d...
Clearmind Medicine Announces Filing of European Patent Application for Novel Psychedelic Compounds for the Treatment of PTSD
Vancouver, Canada, May 05, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of ...
Clearmind Medicine files to sell 22.63M common shares for holders
16:30 EDT Clearmind Medicine (CMND) files to sell 22.63M common shares for holders
Clearmind Medicine Registration statement: Registration filing
Clearmind Medicine filed a registration statement on April 30, 2026, providing details about a securities offering with the SEC.
Clearmind announces evaluation of CMND-100 for breakthrough therapy designation
Clearmind Medicine (CMND) announced that it is evaluating CMND-100, for eligibility for the FDA’s breakthrough therapy designation.
Clearmind Medicine Announces Evaluation of its Psychedelic-Based Treatment (MEAI) for Potential FDA Breakthrough Therapy Designation
Positive clinical results from Alcohol Use Disorder clinical trial may strengthen potential for eligibility for Breakthrough Therapy Designation
Clearmind Medicine Welcomes President Trump's Executive Order as a Historic Catalyst for Psychedelic Innovation and Veteran Mental Health Care
Vancouver, Canada, April 20, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage psychedelic biotech company focused on the discovery and d...
Clearmind Medicine Announced Positive Top-Line Safety Results: CMND-100 Proprietary Psychedelic Treatment Meets Primary Endpoint in AUD Trial
Vancouver, Canada, April 20, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development o...
Clearmind announces DSMB recommendation to continue CMND-100 trial
Clearmind Medicine (CMND) announced Wednesday that its independent Data and Safety Monitoring Board has completed its review and issued a positive recommendation to continue the ongoing FDA-approved P...
Clearmind Medicine Announces Positive Data Safety Monitoring Board Recommendation in ongoing CMND-100 clinical trial
Vancouver, Canada, April 15, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development o...
Clearmind Medicine's CMND-100 Meets Primary Endpoint in FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
Vancouver, Canada, April 14, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development o...
Clearmind Medicine Announces Successful Completion of Treatment and Follow-up for 18 Participants in its Ongoing Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder
Company completed treatment in four additional participate at its Israel clinical site Vancouver, Canada, March 30, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the ...